Market Overview:
The global recombinant human interferon α1b market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic hepatitis B, hairy cell leukemia, and hepatitis C. In addition, the increasing demand for recombinant human interferon α1b for research purposes is also contributing to the growth of this market. However, stringent regulatory requirements and high costs associated with R&D are restraining the growth of this market. On the basis of type, injection accounted for a major share of the global recombinant human interferon α1b market in 2017. This can be attributed to its higher efficacy as compared to other forms such as oral and nasal sprays. On the basis of application, chronic hepatitis B was a leading application segment in 2017 owing to its high prevalence across regions worldwide.
Product Definition:
A recombinant human interferon alpha1b is a protein that is produced through genetic engineering in a laboratory. It is used to treat various infections, including hepatitis C, and certain cancers.
Injection:
Injection is a recombinant human interferon manufactured by Novartis AG. It was approved by the U.S. FDA in 1999 for treatment of patients with chronic non-neurological autoimmune diseases, including Systemic Lupus Erythematosus (SLE), and in 2008 for treatment of relapsing forms of multiple sclerosis.
Spray:
Spray is a fine mist that is usually applied directly to the skin. It can be used for treating viral infections, allergies, and other medical conditions. The active ingredients in spray are absorbed by the skin and then carried to the site of infection where it starts killing bacteria and viruses. Some of these medications may also help reduce itching caused due to allergic reactions.
Application Insights:
The chronic hepatitis B application segment led the global market in 2017. This is owing to a rise in the prevalence of hepatitis B infection, which is estimated to reach around 90 million by 2030. Moreover, a rise in awareness about this disease and its symptoms will further boost demand for recombinant human interferon¢â‚¬â„¢s drugs over the forecast period.
The chronic hepatitis C segment is expected to witness significant growth during the forecast period due largely to an increase in cases of this disease across all regions including North America, Europe and Asia Pacific.
Regional Analysis:
North America dominated the global market in 2017 owing to a rise in awareness about rHIF and presence of key players. Moreover, increasing government funding for research activities is also expected to drive the regional growth over the forecast period. For instance, according to data published by National Cancer Institute (NCI), NCI’s Recombinant Human Interferon Program received approximately USD X million from Congress between fiscal years 1992 and 1994. This program was aimed at accelerating progress against cancer using interferons as a treatment or prophylaxis against cancer-related symptoms such as tumor growth or recurrence.
Asia Pacific region is anticipated to witness lucrative CAGR during the forecast period due to rising incidence of chronic hepatitis B & C infections coupled with growing healthcare expenditure in emerging economies such as China & India.
Growth Factors:
- Increasing incidence of chronic diseases such as hepatitis, cancer, and multiple sclerosis is expected to drive the demand for recombinant human interferon α1b over the forecast period.
- Growing awareness about the benefits of recombinant human interferon α1b is anticipated to boost its demand in the near future.
- Rising number of clinical trials for recombinant human interferon α1b is projected to create new opportunities for this market in the coming years.
- Technological advancements in manufacturing process are likely to propel the growth of this market during the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Recombinant Human Interferon α1b Market Research Report
By Type
Injection, Spray
By Application
Chronic Hepatitis B, Hairy Cell Leukemia, Hepatitis C
By Companies
Beijing Tri-Prime Gene Pharmaceutical Co., Ltd., Shenzhen Kexing Biological Technology Co., Ltd.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
163
Number of Tables & Figures
115
Customization Available
Yes, the report can be customized as per your need.
Global Recombinant Human Interferon α1b Market Report Segments:
The global Recombinant Human Interferon α1b market is segmented on the basis of:
Types
Injection, Spray
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Chronic Hepatitis B, Hairy Cell Leukemia, Hepatitis C
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Beijing Tri-Prime Gene Pharmaceutical Co., Ltd.
- Shenzhen Kexing Biological Technology Co., Ltd.
Highlights of The Recombinant Human Interferon α1b Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Injection
- Spray
- By Application:
- Chronic Hepatitis B
- Hairy Cell Leukemia
- Hepatitis C
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Recombinant Human Interferon α1b Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Recombinant human interferon α1b is a type of medication that helps the body fight infections. It is made from pieces of the virus that have been cut down so they are not as harmful to the body. This makes it easier for your immune system to fight off infection.
Some of the major companies in the recombinant human interferon î±1b market are Beijing Tri-Prime Gene Pharmaceutical Co., Ltd., Shenzhen Kexing Biological Technology Co., Ltd..
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Recombinant Human Interferon α1b Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Recombinant Human Interferon α1b Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Recombinant Human Interferon α1b Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Recombinant Human Interferon α1b Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Recombinant Human Interferon α1b Market Size & Forecast, 2020-2028
4.5.1 Recombinant Human Interferon α1b Market Size and Y-o-Y Growth
4.5.2 Recombinant Human Interferon α1b Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Injection
5.2.2 Spray
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Chronic Hepatitis B
6.2.2 Hairy Cell Leukemia
6.2.3 Hepatitis C
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Recombinant Human Interferon α1b Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Recombinant Human Interferon α1b Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Injection
9.6.2 Spray
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Chronic Hepatitis B
9.10.2 Hairy Cell Leukemia
9.10.3 Hepatitis C
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Injection
10.6.2 Spray
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Chronic Hepatitis B
10.10.2 Hairy Cell Leukemia
10.10.3 Hepatitis C
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Injection
11.6.2 Spray
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Chronic Hepatitis B
11.10.2 Hairy Cell Leukemia
11.10.3 Hepatitis C
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Injection
12.6.2 Spray
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Chronic Hepatitis B
12.10.2 Hairy Cell Leukemia
12.10.3 Hepatitis C
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Injection
13.6.2 Spray
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Chronic Hepatitis B
13.10.2 Hairy Cell Leukemia
13.10.3 Hepatitis C
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Recombinant Human Interferon α1b Market: Competitive Dashboard
14.2 Global Recombinant Human Interferon α1b Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Beijing Tri-Prime Gene Pharmaceutical Co., Ltd.
14.3.2 Shenzhen Kexing Biological Technology Co., Ltd.
